Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in Refractory Severe Aplastic Anemia
NCT07714512Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in severe aplastic anemia (SAA), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jun 2026; status: recruiting.
02
Drugs
isatuximab
03
Conditions
severe aplastic anemia (SAA)
Beyond the preview
Go deeper on NCT07714512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714512.